Trials / Unknown
UnknownNCT03729258
Efficacy and Safety of Modified Release Cefpodoxime Formulation in the Treatment of Acute Sinusitis.
Comparison of the Efficacy and Safety of Immediate (b.i.d) and Modified (q.d.) Release Cefpodoxime Formulations in the Treatment of Acute Sinusitis: a Double-blind, Randomized, Phase III, Non-inferiority Study.
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Neutec Ar-Ge San ve Tic A.Ş · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to compare the efficacy and safety of cefpodoxime 200 mg immediate (b.i.d) and cefpodoxime 400 mg modified release (q.d) tablet formulations in the treatment of acute bacterial rhinosinusitis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Infex 400 MR | Infex (cefpodoxime) 400mg once a day (QD) for 10 days |
| DRUG | Infex 200 IR | Infex (cefpodoxime) 200mg twice a day (BID) for 10 days |
Timeline
- Start date
- 2019-05-15
- Primary completion
- 2023-10-01
- Completion
- 2023-12-01
- First posted
- 2018-11-02
- Last updated
- 2023-01-05
Locations
1 site across 1 country: Turkey (Türkiye)
Source: ClinicalTrials.gov record NCT03729258. Inclusion in this directory is not an endorsement.